H Miles Prince

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. doi request reprint The development of novel immunotherapeutic approaches in multiple myeloma
    Stefan Peinert
    DHMO, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Leuk Lymphoma 49:652-4. 2008
  2. doi request reprint Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol
    Suzanne Arulogun
    Division of Hematology and Medical Oncology, Department of Pathology, Peter MacCallum Cancer Center, St Vincent s Hospital, University of Melbourne, Melbourne, Parkville, Australia
    J Am Acad Dermatol 59:589-95. 2008
  3. pmc Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
    H Miles Prince
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic, Australia
    Eur J Haematol 79:93-9. 2007
  4. pmc Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
    H Miles Prince
    Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
    Leuk Lymphoma 54:69-75. 2013
  5. doi request reprint Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo
    H Miles Prince
    Haematology Service, Peter MacCallum Cancer Center and University of Melbourne, Melbourne, Australia
    J Am Acad Dermatol 67:867-75. 2012
  6. doi request reprint Romidepsin for cutaneous T-cell lymphoma
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Clin Cancer Res 18:3509-15. 2012
  7. pmc Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
    Michael Dickinson
    Department of Haematology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Vic, 3002, Australia
    Invest New Drugs 28:S3-20. 2010
  8. pmc Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell
    Kathy Ka Wai Auyeung
    Pharmacology and Toxicology Laboratory, School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Hong Kong, China
    Invest New Drugs 28:1-13. 2010
  9. ncbi request reprint A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy
    H Miles Prince
    Hematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Biol Blood Marrow Transplant 11:512-20. 2005
  10. doi request reprint In vivo tracking of dendritic cells in patients with multiple myeloma
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    J Immunother 31:166-79. 2008

Detail Information

Publications103 found, 100 shown here

  1. doi request reprint The development of novel immunotherapeutic approaches in multiple myeloma
    Stefan Peinert
    DHMO, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Leuk Lymphoma 49:652-4. 2008
  2. doi request reprint Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol
    Suzanne Arulogun
    Division of Hematology and Medical Oncology, Department of Pathology, Peter MacCallum Cancer Center, St Vincent s Hospital, University of Melbourne, Melbourne, Parkville, Australia
    J Am Acad Dermatol 59:589-95. 2008
    ..Response and survival compare favorably with those of previous studies. Our modified treatment protocol appears to produce outcomes similar to the two-day protocol...
  3. pmc Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
    H Miles Prince
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic, Australia
    Eur J Haematol 79:93-9. 2007
    ..To conduct a systematic review of the efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed/refractory multiple...
  4. pmc Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
    H Miles Prince
    Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
    Leuk Lymphoma 54:69-75. 2013
    ..The safety profile of DD in CD25 low-expression disease was similar to that in CD25+ disease. These findings suggest that CD25 low expression does not preclude a meaningful clinical response to DD in patients with CTCL...
  5. doi request reprint Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo
    H Miles Prince
    Haematology Service, Peter MacCallum Cancer Center and University of Melbourne, Melbourne, Australia
    J Am Acad Dermatol 67:867-75. 2012
    ..Spontaneous remission is recognized in mycosis fungoides (MF) and Sézary syndrome (SS)...
  6. doi request reprint Romidepsin for cutaneous T-cell lymphoma
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Clin Cancer Res 18:3509-15. 2012
    ..Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side effect profile...
  7. pmc Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
    Michael Dickinson
    Department of Haematology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Vic, 3002, Australia
    Invest New Drugs 28:S3-20. 2010
    ..We also focus on the immune effects of these agents...
  8. pmc Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell
    Kathy Ka Wai Auyeung
    Pharmacology and Toxicology Laboratory, School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Hong Kong, China
    Invest New Drugs 28:1-13. 2010
    ..This suggests that the anticarcinogenic activities of different herbal flavonoids may involve both common and differential mechanisms of action, which could be developed as potential anticancer drugs...
  9. ncbi request reprint A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy
    H Miles Prince
    Hematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Biol Blood Marrow Transplant 11:512-20. 2005
    ..022) and in the duration of intravenous opiates ( P=.0006). We conclude that PV701 mouthwash is readily administered with minimal side effects at a dose of 1215 mg/d, and further investigation of this agent is warranted...
  10. doi request reprint In vivo tracking of dendritic cells in patients with multiple myeloma
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    J Immunother 31:166-79. 2008
    ..SC and ID routes produced similar levels of DC migration...
  11. ncbi request reprint An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia
    Leuk Lymphoma 48:46-55. 2007
    ..Prognostic factors identified included B2M (PFS) and advanced age (PFS and OS). Overall, thalidomide demonstrated an ORR approaching 30%, with low CR rate of 1.6% and VTE and DDI incidences of 3% and 15%, respectively...
  12. ncbi request reprint Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia
    Br J Haematol 126:536-45. 2004
    ..There were also fewer platelet transfusions required (43% vs. 100%; P = 0.009). We conclude that EXE cells enhance both neutrophil and platelet recovery and reduce febrile neutropenia, platelet transfusion and hospital re-admission...
  13. ncbi request reprint How I treat mycosis fungoides and Sézary syndrome
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia
    Blood 114:4337-53. 2009
    ..It is appropriate to consider patients for novel agents within clinical trials if they have failed front-line therapy and before chemotherapy is used...
  14. doi request reprint Clinical studies of histone deacetylase inhibitors
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Australia and University of Melbourne, Parkville, Victoria, Australia
    Clin Cancer Res 15:3958-69. 2009
    ..The use of the biomarker of histone hyperacetylation has been useful as a guide to target specificity, but generally does not predict for response and the search for more clinically relevant biomarkers must continue...
  15. doi request reprint Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
    H Miles Prince
    Peter MacCallum Cancer Centre Melbourne, Melbourne, Victoria, Australia
    Future Oncol 5:601-12. 2009
    ..In this article, we discuss the preclinical data on panobinostat and emerging data from Phase I and II studies in cancer patients...
  16. ncbi request reprint Management of the primary cutaneous lymphomas
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas J Dermatol 44:227-40; quiz 241-2. 2003
    ..Newer therapies include the synthetic retinoid bexarotene, the immunotoxin conjugate denileukin diftitox, interleukin-12 and monoclonal antibodies such as alemtuzumab and rituximab...
  17. ncbi request reprint A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
    H Miles Prince
    University of Melbourne and Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Cancer Res 11:5504-14. 2005
    ..Future studies should use newer COX-2 inhibitors with thalidomide, or their respective derivatives...
  18. doi request reprint A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
    Simon J Harrison
    Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Blood 118:6274-83. 2011
    ..2 (95% CI: 5.5-19.6) months, and the median OS was > 36 months. This regimen shows activity with manageable toxicity and warrants further evaluation. This trial was registered at www.clinicaltrials.gov as NCT00431990...
  19. ncbi request reprint Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma
    Andrew P Grigg
    Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia
    Leuk Lymphoma 51:641-9. 2010
    ..Long-term follow-up demonstrates that autografting may result in durable remissions in a meaningful minority of patients with relapsed follicular NHL...
  20. ncbi request reprint Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
    Nicole Wong Doo
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 54:1465-72. 2013
    ..We propose that its use should be explored as part of a tandem approach in patients undergoing initial SCT who are at high risk of early relapse...
  21. doi request reprint Histone deacetylase inhibitors in lymphoma and solid malignancies
    Walid Rasheed
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
    Expert Rev Anticancer Ther 8:413-32. 2008
    ..In this review we discuss the recent advances in the clinical development of HDACi and their current therapeutic role in lymphoma and solid malignancies...
  22. doi request reprint Emergence of central nervous system myeloma in the era of novel agents
    Shane A Gangatharan
    Department of Haematology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Australia
    Hematol Oncol 30:170-4. 2012
    ..Whether this is due to improved overall survival or specific characteristics of these therapies is not clear. Despite the availability of novel agents, survival after CNS MM remains poor...
  23. ncbi request reprint Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma
    Constantine S Tam
    Leukemia Lymphoma Service, Hematology Service, Peter MacCallum Cancer Center, The Alfred Hospital, University of Melbourne, Victoria, Australia
    Cancer 106:2412-20. 2006
    ..The combination of fludarabine, cyclophosphamide, and rituximab (FC-R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity...
  24. doi request reprint A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation
    Amit Khot
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma Leuk 13:42-7. 2013
    ..We prospectively explored a strategy that used prophylactic delayed filgrastim only in patients with risk factors...
  25. doi request reprint [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
    Saar Gill
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma 8:159-65. 2008
    ..Positron emission tomography (PET) is an important imaging modality in the staging and response assessment of patients with lymphoma, but data on its specific use in mantle cell lymphoma (MCL) are lacking...
  26. ncbi request reprint Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents
    Mark Bishton
    Peter MacCallum Cancer Center, Department of Haematology, Melbourne, Australia
    Expert Rev Anticancer Ther 7:1439-49. 2007
    ....
  27. ncbi request reprint Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients
    Saar Gill
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Ann Hematol 87:727-34. 2008
    ..These results indicate a considerable rate of prolonged haematological toxicity after hyper-CVAD and a modest rate of MDS at this limited follow-up. These findings likely reflect cumulative damage to haematopoietic stem cells...
  28. ncbi request reprint Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
    Ashley P Ng
    Haematology Service, PeterMacCallum Cancer Centre, Melbourne, Australia
    Leuk Lymphoma 48:596-600. 2007
    ..Low-grade FDG-avidity on interim restaging at sites of bone involvement by DLBCL at diagnosis, appears to be less predictive of disease progression than residual nodal or extra-nodal soft tissue abnormality by PET...
  29. ncbi request reprint Predicting durable remissions following thalidomide therapy for relapsed myeloma
    Hang Quach
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Leuk Lymphoma 50:223-9. 2009
    ..001). The OS for these groups were >69.8, 35.4 and 11.7 months, respectively (p < 0.001). These findings support the therapeutic goal of achieving 'maximum depth of response' in patients with relapsed myeloma...
  30. ncbi request reprint Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy
    Michael Dickinson
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Br J Haematol 150:39-45. 2010
    ..Although those with positive scans can still be salvaged with current treatments, PET may useful for selecting patients eligible for novel consolidation strategies after salvage therapies...
  31. ncbi request reprint Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia
    Constantine S Tam
    Department of Haematology, Peter MacCallum Cancer Centre, A Beckett Street, East Melbourne, Victoria 8006, Australia
    Clin Lymphoma Myeloma 6:136-9. 2005
    ..No cases of secondary myelodysplasia or leukemia were encountered...
  32. ncbi request reprint The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization
    Colm Keane
    Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
    Hematol Oncol 24:159-63. 2006
    ..There were no significant differences in PBSC yields following cycles 2A, 2B and 3A. Hyper-CVAD has substantial stem cell toxicity which can be readily circumvented by using the early chemotherapy cycles for mobilization...
  33. doi request reprint A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®))
    Simon J Harrison
    Haematology Service, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Epigenomics 4:571-89. 2012
    ..This report outlines the laboratory and clinical development of the compound as a single agent that has more recently been evaluated in combination with other anticancer therapeutics, such as proteasome inhibitors...
  34. ncbi request reprint Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
    Linda Mileshkin
    Division of Haematology and Medical Oncology, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Center, St Andrew s Place, East Melbourne, Vic, Australia
    Haematologica 92:1075-82. 2007
    ..We assessed laboratory and clinical parameters in patients with myeloma treated with thalidomide as potential prognostic markers and looked for changes with therapy...
  35. ncbi request reprint The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders
    Mark N Polizzotto
    Department of Hematology, The Alfred Hospital, Melbourne, Victoria, Australia
    Cancer 107:773-80. 2006
    ..Despite the prevalence of such disorders in older patients, the effect of increasing age on the deliverability of these regimes has not been assessed...
  36. doi request reprint Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab
    Violet Kieu
    St Vincent s Hospital Melbourne, Fitzroy, Vic, Australia
    Australas J Dermatol 50:202-6. 2009
    ..Rituximab appears to have activity in refractory SCLE and clinical trials are required to further assess this potential therapy...
  37. ncbi request reprint Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications
    Lee Mei Yap
    The University of Melbourne, Department of Medicine Dermatology, St Vincent s Hospital Melbourne, Victoria, Australia
    Australas J Dermatol 44:110-5. 2003
    ..Further large prospective studies comparing the WHO and EORTC classifications are required to more clearly delineate the outcomes of the increasing number of patients who are classified as DLBCL by the WHO system...
  38. doi request reprint Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia
    Stefan Peinert
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 51:2188-97. 2010
    ..F-combination therapy is highly active in WM, both untreated and alkylator-refractory. However, a possible contribution to the cumulative risk of treatment-related MDS/AML requires ongoing monitoring...
  39. doi request reprint The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
    Andy K Hsu
    Hematology Immunology Translational Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Blood 117:1605-13. 2011
    ..Our findings indicate that lenalidomide immunostimulatory effects on patient NK cells are severely blunted by concurrent dexamethasone administration...
  40. doi request reprint Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure
    Andrew Spencer
    Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Victoria, Australia
    J Clin Oncol 27:1788-93. 2009
    ..This study assessed whether the addition of thalidomide consolidation following ASCT would improve the durability of responses achieved and overall survival...
  41. ncbi request reprint Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation
    Ashley P Ng
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia
    Haematologica 90:1672-9. 2005
    ....
  42. doi request reprint Mantle cell lymphoma with central nervous system involvement: frequency and clinical features
    Saar Gill
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Br J Haematol 147:83-8. 2009
    ..While not routinely justified for all patients, CNS prophylaxis may particularly benefit patients with blastic histology at diagnosis, or those with systemic relapse after first-line treatment...
  43. ncbi request reprint Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, East Melbourne, 8006, Victoria, Australia
    Ann Hematol 93:1193-200. 2014
    ..Thus, surveillance imaging of patients with TrIL achieving CMR is of limited clinical benefit. PET-CT should be reserved for evaluation of clinically suspected relapse. ..
  44. pmc Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia
    David S Ritchie
    1 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia 2 Hematology Immunology Translational Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia 3 Cancer Immunology Research Program, Peter MacCallum Cancer Centre, East Melbourne, Australia 4 Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia 5 Centre for Blood Cell Therapies, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Mol Ther 21:2122-9. 2013
    ..Our study supports the feasibility and safety of CAR-T-cell therapy in high-risk AML, and demonstrates durable in vivo persistence...
  45. doi request reprint Panobinostat in lymphoid and myeloid malignancies
    Amit Khot
    Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Expert Opin Investig Drugs 22:1211-23. 2013
    ..Activity has been demonstrated in hematological diseases, such as cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma (HL), myeloma and myeloid malignancies...
  46. pmc Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
    Jennifer A Westwood
    Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 102:19051-6. 2005
    ..This study supports the use of humanized gene-modified T cells as a potential therapy for Le(Y+) malignancies...
  47. doi request reprint Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide
    Mark J Bishton
    Cancer Research Division, The Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne 3002, Victoria, Australia
    Thromb Res 131:514-20. 2013
    ....
  48. ncbi request reprint Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections
    Peter Gambell
    Peter MacCallum Cancer Centre, Melbourne, Australia
    Biol Blood Marrow Transplant 18:763-72. 2012
    ....
  49. doi request reprint Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
    Leigh Ellis
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Cancer Res 14:4500-10. 2008
    ..Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat...
  50. ncbi request reprint Immunotherapy of multiple myeloma: the start of a long and tortuous journey
    Simon J Harrison
    DHMO, Peter MacCallum Cancer Centre and Locked Bag 1, A becket Street, Melbourne, Victoria 8006, Australia
    Expert Rev Anticancer Ther 6:1769-85. 2006
    ....
  51. ncbi request reprint A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies
    Constantine S Tam
    Leukemia Lymphoma Service, Department of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer 101:2042-9. 2004
    ..The authors analyzed their experience with patients treated with the fludarabine-mitoxantrone (FM) or fludarabine-cyclophosphamide (FC) regimens to develop a predictive model for infections...
  52. doi request reprint The use of experimental murine models to assess novel agents of hematopoietic stem and progenitor cell mobilization
    Kirsten E Herbert
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Biol Blood Marrow Transplant 14:603-21. 2008
    ..Technical aspects regarding mobilization regimens and control arms, and choice of experimental animals are also discussed...
  53. doi request reprint Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications
    Piers Blombery
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Victoria, Australia
    Ann Hematol 90:1167-72. 2011
    ..4 g/kg) to reduce infectious complications in a large cohort of patients with myeloma undergoing ASCT. In the absence of data supporting efficacy in this context, there appears to be no benefit in the routine use of IVIG for this purpose...
  54. ncbi request reprint Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
    Linda Mileshkin
    Department of Haematology and Medical Oncology, and Statistical Centre, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    Blood 102:69-77. 2003
    ..Interferon may improve response in selected patients, but is often not tolerated. The inferior outcome demonstrated in those with the identified prognostic factors is important in planning management for such patients...
  55. doi request reprint Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
    Michael Dickinson
    Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Br J Haematol 147:97-101. 2009
    ..This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual...
  56. ncbi request reprint Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma
    Maher K Gandhi
    Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
    Clin Cancer Res 12:460-4. 2006
    ..Latent Epstein-Barr virus (EBV) genomes are found in the malignant cells of approximately one-third of Hodgkin's lymphoma (HL) cases. Detection and quantitation of EBV viral DNA could potentially be used as a biomarker of disease activity...
  57. ncbi request reprint Treatment-related myelodysplasia following fludarabine combination chemotherapy
    Constantine S Tam
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Haematologica 91:1546-50. 2006
    ..5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy...
  58. ncbi request reprint Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring
    Linda Mileshkin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Clin Oncol 24:4507-14. 2006
    ..We assessed the time course of occurrence, possible predictive factors, and the utility of serial nerve electrophysiological studies (NES) for detecting onset of neuropathy...
  59. ncbi request reprint The potential of histone deacetylase inhibitors for the treatment of multiple myeloma
    H Miles Prince
    Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Leuk Lymphoma 49:385-7. 2008
    ..Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored...
  60. ncbi request reprint Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy
    Florent Cachin
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, 12 Cathedral Place, East Melbourne, VIC 3002, Australia
    J Clin Oncol 24:3026-31. 2006
    ....
  61. ncbi request reprint Histone deacetylase inhibitors in cancer therapy
    Walid K Rasheed
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
    Expert Opin Investig Drugs 16:659-78. 2007
    ..Although still early in drug development, there is a picture that is starting to develop as to the common toxicities and which tumors seem to be the most susceptible to this class of drugs...
  62. doi request reprint Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade
    Jayne S Sutherland
    Department of Immunology, Monash University, Clayton, Victoria, Australia
    Clin Cancer Res 14:1138-49. 2008
    ..To determine if temporarily blocking sex steroids prior to stem cell transplantation can increase thymus function and thus enhance the rate of T cell regeneration...
  63. ncbi request reprint Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia
    Fiona Chionh
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Leuk Lymphoma 46:603-5. 2005
    ..Thus, in patients with hematological malignancies who develop significant gastrointestinal symptoms, we recommend that endoscopic investigations and biopsies are performed to exclude IA as a potential cause...
  64. doi request reprint Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma
    Mark A Dawson
    Clinical Haematology Bone Marrow Transplant Department, The Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria, Australia 3181
    Clin Cancer Res 15:714-22. 2009
    ..However, there remains a paucity of data in patients treated with bortezomib that accurately delineates and identifies such patients. This information is crucial to guide management...
  65. pmc Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals
    Shuo Li
    Burnet Institute, Melbourne, Victoria, Australia
    PLoS ONE 7:e39368. 2012
    ..Our data suggested that Mo-DC therapy induced complex immune responses in vivo that may or may not lead to clinical benefit...
  66. doi request reprint Alloreactive natural killer cells in hematopoietic stem cell transplantation
    Hollie J Pegram
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, Melbourne, Australia
    Leuk Res 35:14-21. 2011
    ..Further understanding of conditioning and mechanisms to reduce graft versus host disease (GVHD) will improve our ability to manipulate NK cells in HSCT...
  67. ncbi request reprint Treatment strategies in elderly patients with multiple myeloma: current status
    Hang Quach
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia
    Drugs Aging 24:829-50. 2007
    ....
  68. ncbi request reprint Denileukin diftitox and vision loss
    J B Ruddle
    Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
    Leuk Lymphoma 48:655-6. 2007
  69. ncbi request reprint Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies
    Constantine S Tam
    Hematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer 100:2181-9. 2004
    ..In the current study, the authors analyzed their experience with an attenuated dose regimen to determine whether equivalent efficacy could be achieved with reduced toxicity...
  70. ncbi request reprint Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review
    Constantine S Tam
    Haematology Service, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Leuk Lymphoma 45:705-10. 2004
    ..We review the current literature on this newly described entity, highlighting the importance of its recognition...
  71. ncbi request reprint Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases
    Glen A Kennedy
    Haematology Service, Peter MacCallum Cancer Centre, St Vincent s Hospital, Melbourne, Victoria, Australia
    Australas J Dermatol 45:34-7. 2004
    ..No adverse effects were observed. To date, disease progression has occurred in one case during overall follow up at 6 and 17 months. The potential role of rituximab in the treatment of these lymphomas is discussed...
  72. doi request reprint The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution
    Kirsten E Herbert
    Peter MacCallum Cancer Centre, Department of Hematology and Medical Oncology, Victoria, Australia
    Expert Opin Biol Ther 10:113-25. 2010
    ..The emergence of other novel agents for HSPC mobilization such as plerixafor (AMD3100, Mozobil) will further demarcate the role of Ancestim as a second- or third-line mobilization agent for the mobilization-refractory patient...
  73. pmc Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report
    David Ritchie
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria 3002, Australia
    Haematologica 94:1618-22. 2009
    ..These observations suggest that vigilance for DNA virus reactivation is needed to quantify the risk in patients treated with histone deacetylase inhibitors...
  74. doi request reprint Managing multiple myeloma in the elderly: are we making progress?
    Hang Quach
    Department of Clinical Hematology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia
    Expert Rev Hematol 4:301-15. 2011
    ..Here, we review the outcomes of elderly patients with multiple myeloma over recent years and focus on the current treatment options available for this group...
  75. ncbi request reprint Cutaneous lymphomas: which pathological classification?
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Pathology 34:36-45. 2002
    ..This classification can encompass all the conditions and aligns the cutaneous lymphomas with the broader systemic lymphoproliferative conditions...
  76. ncbi request reprint Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases
    Hope V Dinh
    Department of Dermatology, St Vincent s Hospital, Melbourne, Australia
    J Am Acad Dermatol 56:148-53. 2007
    ..They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis...
  77. ncbi request reprint Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome
    Simon D J Gibbs
    Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Australia
    Eur J Haematol 73:447-9. 2004
    ..We present the case of a 65-yr-old man who was successfully treated with alemtuzumab monotherapy for both disorders, but at a cost of severe infectious morbidity and prolonged pancytopenia...
  78. ncbi request reprint The adverse prognostic impact of advanced age in multiple myeloma
    Linda Mileshkin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Leuk Lymphoma 46:951-66. 2005
    ....
  79. doi request reprint A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment
    Senthil Lingaratnam
    Pharmacy Department, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
    Aust Health Rev 35:491-500. 2011
    ....
  80. doi request reprint Successful treatment of lymphomatoid papulosis with photodynamic therapy
    Michelle Rodrigues
    Dermatology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas J Dermatol 50:129-32. 2009
    ....
  81. ncbi request reprint Myeloma, thalidomide and thrombosis
    Dirk Honemann
    Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 47:2273-5. 2006
  82. ncbi request reprint Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma
    Melita K Kenealy
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Pharmacotherapy 26:1205-6; discussion 1206. 2006
  83. ncbi request reprint The troublesome toxicity of peripheral neuropathy with thalidomide
    Linda Mileshkin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 47:2276-9. 2006
  84. ncbi request reprint Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells
    Kirsten E Herbert
    Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Transplantation 83:375-84. 2007
    ....
  85. ncbi request reprint Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer
    Robert Blum
    Division of Oncology at Peter MacCallum Cancer Institute, Melbourne, Australia
    Am J Clin Oncol 25:368-70. 2002
    ..A mixed response requires further investigation, particularly in the case of persisting solitary abnormalities in the neck...
  86. doi request reprint Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation
    Suzanne O Arulogun
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, USA
    Blood 112:3082-7. 2008
    ..The median OS from diagnosis of LCT was 2 years. We confirm that the incidence of LCT is strongly dependent on tumor stage at diagnosis, and we demonstrate a much lower overall risk of LCT than previously reported...
  87. ncbi request reprint Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Meletios Dimopoulos
    University of Athens School of Medicine, Athens, Greece
    N Engl J Med 357:2123-32. 2007
    ..This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma...
  88. ncbi request reprint Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression
    Susan J Morgan
    Clin Cancer Res 10:3572-5. 2004
  89. ncbi request reprint Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy
    Steven W Lane
    Department of Haematology, School of Medicine, University of Queensland, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Australia 4102
    Leuk Lymphoma 47:1813-7. 2006
    ..Once per cycle dosing of pegfilgrastim appears safe and as effective as daily G-CSF for supporting the hyper-CVAD chemotherapy regimen...
  90. ncbi request reprint Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma
    Kenneth C Anderson
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, USA
    Semin Hematol 42:S1-2. 2005
  91. ncbi request reprint Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients
    Nadege Bercovici
    IDM, Hopital Europeen Georges Pompidou, Unité d Immunologie Biologique, EA 4054 Université Paris, France
    J Immunother 31:101-12. 2008
    ..The differential expression of perforin and IFN-gamma by antitumor and antiviral CD8+ T cells supports that the sole use of IFN-gamma production to monitor T cells overlooks functional T-cell subpopulations triggered by vaccines...
  92. ncbi request reprint A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma
    Dirk Honemann
    Leuk Lymphoma 46:945-7. 2005
  93. ncbi request reprint Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab
    Kirsten E Herbert
    Blood 101:1654. 2003
  94. doi request reprint Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)
    Lei Zhang
    J Clin Oncol 26:332-3; discussion 333-4. 2008
  95. ncbi request reprint The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer
    Tara Seshadri
    Peter MacCallum Centre, Melbourne, Vic
    Med J Aust 182:453-7. 2005
    ..To evaluate the frequency and management of anaemia in Australian adults with solid and haematological malignancies...
  96. ncbi request reprint Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases
    Ashley P Ng
    Haematologica 91:143-4. 2006
    ..We present five cases to highlight the need for greater awareness of this entity amongst pathologists such that aggressive treatment be considered given the generally poor prognosis...
  97. ncbi request reprint Cefotetan-induced life-threatening haemolysis
    Heather E Robinson
    Med J Aust 184:251. 2006
  98. ncbi request reprint Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase
    Rudolf J Schrover
    Novartis Pharmaceuticals Australia Pty Ltd North Ryde, New South Wales, Australia
    Leuk Lymphoma 47:1069-81. 2006
    ..8 years for every 25 percentage point increase in MCR rate. The results support the use of the proportion of patients with CML in the chronic phase with an MCR to estimate overall long-term survival...
  99. ncbi request reprint Methotrexate-induced lymphoproliferative disorder in a patient with Sézary syndrome
    Michelle Rodrigues
    Leuk Lymphoma 47:2257-9. 2006
  100. ncbi request reprint Gastric involvement of plasmacytoma associated with t(4:14) and chromosome 13 deletion
    Heather Robinson
    Leuk Lymphoma 47:1973-5. 2006
  101. doi request reprint A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, USA
    Blood 112:2667-74. 2008
    ..001). ECP was generally well tolerated. These results suggest that ECP may have a steroid-sparing effect in the treatment of cGVHD. Clinical trials registered at www.ClinicalTrials.gov as NCT00054613...